Charles Schwab Investment Management Inc Astria Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 314,265 shares of ATXS stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
314,265
Previous 124,538
152.34%
Holding current value
$2.88 Million
Previous $1.13 Million
205.38%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ATXS
# of Institutions
107Shares Held
48.6MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$59.3 Million1.87% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$46.7 Million0.78% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$36.6 Million3.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$32.5 Million6.36% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$32.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $139M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...